

# COVID-19 Therapeutics Strategy

THURSDAY 6 MAY 2021

Vaccination rates are increasing across the EU, but therapeutics or treatments are vital to treat those people who are still falling ill and reduce the rate of **acute** and **severe COVID**.



## TO DATE:

1

Number of authorised COVID-19 therapeutics

3

Number of therapeutics under rolling review (pre-authorisation)

57

Number of potential therapeutics the European Medicines Agency has advised on

70

Number of joint procurement contracts for medicines

## WITH THE THERAPEUTICS STRATEGY:

3-5

Newly authorised medicines in 2021

3

New joint procurements of therapeutics

7

New rolling reviews

# THE STRATEGY PROMOTES AN END-TO-END APPROACH TO COVID-19 THERAPEUTICS:

## RESEARCH, DEVELOPMENT AND INNOVATION

Set up a **'therapeutics innovation booster'** to develop a clear overview of therapeutics projects under development in order to better support the most promising ones from preclinical research to market authorisation.



## ACCESS AND SWIFT APPROVAL OF CLINICAL TRIALS

**Facilitate authorisations** at national level to encourage large, multi-country clinical trials.

Invest **€5 million** in **clinical trials safety assessments** and improving safety data.

Provide financial support of **€2 million** for **expedited and coordinated assessments** to facilitate approval of clinical trials.


Invest in producing **high-grade material for clinical trials**.



## SCANNING FOR CANDIDATE THERAPEUTICS

Invest **€5 million** to **map treatments** in their development stage, production capacities and supply chains.

Draw up a **list of 10 potential therapeutics** including the 5 most promising ones by June.



## SUPPLY CHAINS AND DELIVERY OF MEDICINES

Fund a **€40 million preparatory action** to support flexible manufacturing and access for COVID-19 therapeutics under the EU Fab project.


HERA Incubator will help manufacturers and other industrial players team up to produce therapeutics via a dedicated matchmaking event.



## REGULATORY FLEXIBILITY

Authorise **3 additional therapeutics** and start **7 rolling reviews** by end-2021.

**Health data pilot project** to give EU medical regulators quicker access to safety and efficacy data.



## JOINT PROCUREMENT AND FINANCING

Conclude **3 new joint procurement contracts** for authorised COVID-19 medicines by end-2021.

Explore the use of **advance purchase agreement** to boost the development and production of therapeutics.

Streamline solutions to secure faster access to medicines with:

- shorter administrative deadlines
- an allocation mechanism for scarce products
- minimum orders in the first few months
- no parallel national procurement for the same products or services.

## INTERNATIONAL COOPERATION

Fair distribution of therapeutics, notably through the **Access to COVID-19 Tools Accelerator**

